GlassScriptPhysician profile
Krishna M Malireddi
NPI 1780778746
$3,156.29
in general payments reported to CMS, 2019-2025
34 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $143 · 2021: $274 · 2022: $277 · 2023: $759 · 2024: $623 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $777.61 | 2019-2022 | |
| Travere Therapeutics, INC. | $389.51 | 2022-2024 | |
| Amgen INC. | $269.41 | 2023-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $147.97 | 2019 | |
| Vifor Pharma, INC. | $136.98 | 2019-2025 | Veltassa |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2023 | Livtencity |
| Aurinia Pharma U.S., INC. | $113.51 | 2021 | |
| Corcept Therapeutics | $112.25 | 2023-2024 | Korlym |
| Glaxosmithkline, LLC. | $102.17 | 2023-2025 | Benlysta, Jesduvroq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.23 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $83.18 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $73.12 | 2022-2025 | Farxiga |
| Alexion Pharmaceuticals, INC. | $70.29 | 2019 | |
| Xeris Pharmaceuticals, INC. | $62.00 | 2024-2025 | Recorlev, Keveyis |
| Novo Nordisk INC | $53.11 | 2023-2024 | Ozempic, Wegovy, Rybelsus |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $49.32 | 2024-2025 | Tarpeyo |
| Janssen Biotech, INC. | $47.83 | 2024 | Tremfya |
| Insulet Corporation | $42.45 | 2024 | Omnipod |
| Ardelyx, INC. | $39.51 | 2025 | Ibsrela |
| Lilly USA, LLC | $39.27 | 2022-2023 | Mounjaro |
| Horizon Therapeutics Plc | $36.04 | 2022 | |
| Alnylam Pharmaceuticals INC. | $34.59 | 2025 | Oxlumo |
| Genentech USA, INC. | $34.52 | 2019-2020 | |
| Dexcom, INC. | $29.63 | 2022-2023 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $24.98 | 2023 | |
| Apellis Pharmaceuticals, INC. | $22.17 | 2025 | |
| Fresenius Kabi USA, LLC | $21.05 | 2024 | Idacio |
| Teva Pharmaceuticals USA, INC. | $20.87 | 2021 | |
| Sobi, INC | $20.68 | 2024 | |
| Ucb, INC. | $17.28 | 2023 | Cimzia |
| Recordati_rare_diseases_inc. | $17.07 | 2022 | |
| Eusa Pharma (US) LLC | $17.07 | 2022 | |
| Amryt Pharma Holdings LTD | $13.71 | 2023 | Mycapssa |
| Merck Sharp & Dohme LLC | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Malireddi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.